Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Jintian Group Said to Plan $400 Million Hong Kong Initial Offer

Jan. 16 (Bloomberg) -- Jintian Group, a Chinese pharmaceutical distributor, may seek about $400 million in an initial public offering in Hong Kong, according to two people with knowledge of the matter.

The company, based in Heilongjiang province, plans to start the offering next year, said the people, asking not to be identified because the information is private. Jintian is selecting investment banks to arrange the sale, they said.

Jintian operates drug stores across the northeast Chinese province that borders Russia. Two calls to the company’s office in Jiamusi city seeking comment went unanswered.

Shanghai Pharmaceuticals Holding Co., the country’s second-largest drug distributor, raised $2.1 billion in Hong Kong in May 2011. It was the biggest first-time share sale by a Chinese pharmaceutical company in the city, Bloomberg data show. The company has fallen 30 percent from its offer price.

Shanghai Fosun Pharmaceutical (Group) Co., which raised $516 million in October, has lost 1.4 percent from its offer price.

To contact the reporter on this story: Fox Hu in Hong Kong at fhu7@bloomberg.net

To contact the editor responsible for this story: Philip Lagerkranser at lagerkranser@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.